Content Type: Commentary & Opinion

Antibiotic Development Incentives That Reflect Societal Value of Antibiotics (Reply)

March 16, 2026

The FDA Amendments Act of 2007—Assessing Its Effects a Decade Later

March 16, 2026

Is the Concept of Clinical Equipoise Still Relevant to Research?

March 16, 2026

Improving the Use of FDA Advisory Committees

March 16, 2026

Prioritization of Generic Drug Review (Reply)

March 16, 2026

The Regulatory Accountability Act of 2017—Implications for FDA Regulation and Public Health

March 16, 2026

Reforms to Accelerated Approval of New Medicines: Long Overdue

March 16, 2026

COVID-19 Antivirals Must Not Affect HIV Drug Supply

March 16, 2026

Conflict of Interest Disclosure in Early Education of Medical Students

March 16, 2026

Precision Medicine and the FDA’s Draft Guidance on Laboratory-Developed Tests

March 16, 2026

Underrepresentation of Older Adults in Cancer Trials

March 16, 2026

Drug Prices, Rebates, and Discounts

March 16, 2026